EMPIRIKAL – A Double Blind Randomized Controlled Investigation into the efficacy of Mirococept (APT070) for preventing ischaemia-reperfusion injury in the kidney allograft (EMPIRIKAL)

Trial Profile

EMPIRIKAL – A Double Blind Randomized Controlled Investigation into the efficacy of Mirococept (APT070) for preventing ischaemia-reperfusion injury in the kidney allograft (EMPIRIKAL)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Mirococept (Primary)
  • Indications Reperfusion injury
  • Focus Therapeutic Use
  • Acronyms EMPIRIKAL
  • Most Recent Events

    • 11 Mar 2016 Accrual to Date is 3% as per United Kingdom Clinical Research Network record.
    • 11 Mar 2016 Planned End Date changed from 30 Apr 2016 to 31 Mar 2017 as per United Kingdom Clinical Research Network record.
    • 04 Nov 2015 Accrual to Date is 1% as per United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top